Johnson & Johnson Announces FDA Approval Of IMAAVY
30/4 15:24
(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval is supported by data from the ongoing Vivacity-MG3 study....